Lennar (NYSE:LEN) was upgraded by Citigroup (NYSE:C) from sell to neutral with a price target of $35, as its stock price has been underperforming its peers, despite growth that its above average.
Shares are higher by nearly four tenths of a percent.
ARIAD Pharma (NASDAQ:ARIA) had its price target raised by Jefferies (JEF) to $28, as efficacy data for the AP26113 drug is encouraging. A buy rating was issued.
Shares are lower by about six tenths of a percent.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.